US FDA to boost inspections of drug manufacturing units in India

FDA

US FDA to boost inspections of drug manufacturing units in India

Feb 27 (Reuters) – The U.S. drug regulator is set to increase the number of inspections at Indian drug manufacturing units in 2024 amid growing concerns over the quality of drugs, a top executive for the Food and Drug Administration (FDA) told Reuters.
 
The FDA conducted more than 200 inspections in 2023 in India, picking up after a lull in unannounced inspections during the pandemic.
 
We are putting every effort into increasing the number of inspections … (and) requesting more drug investigators to be stationed here,” FDA Country Director (India) Sarah McMullen said on Tuesday.
 
The development comes as India’s $42-billion pharmaceuticals industry works to grow its global presence, with the government pushing drug producers to implement good manufacturing practices to match global standards.
 

/by
You might also like
FDAFDA rejects Amneal’s extended-release Parkinson’s drug
FDA, stop signFDA wants more answers before releasing clinical hold on MaaT’s GvHD drug
Johnson & JohnsonMaker of MDMA-assisted PTSD treatment to seek US regulatory nod
Eli LillyUS FDA declines to approve Eli Lilly’s bowel disease drug
FDAFDA assessing impact of damage at Pfizer plant
MerckMerck accused of downplaying early evidence of drug’s brain impact
Johnson & JohnsonFDA awarded record number of review designations to CRISPR drugs in 2023
Johnson & JohnsonJ&J wins FDA nod for pulmonary arterial hypertension combo pill